Unknown

Dataset Information

0

Establishing long-term efficacy in chronic disease: use of recursive partitioning and propensity score adjustment to estimate outcome in MS.


ABSTRACT:

Context

Establishing the long-term benefit of therapy in chronic diseases has been challenging. Long-term studies require non-randomized designs and, thus, are often confounded by biases. For example, although disease-modifying therapy in MS has a convincing benefit on several short-term outcome-measures in randomized trials, its impact on long-term function remains uncertain.

Objective

Data from the 16-year Long-Term Follow-up study of interferon-beta-1b is used to assess the relationship between drug-exposure and long-term disability in MS patients.

Design/setting

To mitigate the bias of outcome-dependent exposure variation in non-randomized long-term studies, drug-exposure was measured as the medication-possession-ratio, adjusted up or down according to multiple different weighting-schemes based on MS severity and MS duration at treatment initiation. A recursive-partitioning algorithm assessed whether exposure (using any weighing scheme) affected long-term outcome. The optimal cut-point that was used to define "high" or "low" exposure-groups was chosen by the algorithm. Subsequent to verification of an exposure-impact that included all predictor variables, the two groups were compared using a weighted propensity-stratified analysis in order to mitigate any treatment-selection bias that may have been present. Finally, multiple sensitivity-analyses were undertaken using different definitions of long-term outcome and different assumptions about the data.

Main outcome measure

Long-Term Disability.

Results

In these analyses, the same weighting-scheme was consistently selected by the recursive-partitioning algorithm. This scheme reduced (down-weighted) the effectiveness of drug exposure as either disease duration or disability at treatment-onset increased. Applying this scheme and using propensity-stratification to further mitigate bias, high-exposure had a consistently better clinical outcome compared to low-exposure (Cox proportional hazard ratio = 0.30-0.42; p<0.0001).

Conclusions

Early initiation and sustained use of interferon-beta-1b has a beneficial impact on long-term outcome in MS. Our analysis strategy provides a methodological framework for bias-mitigation in the analysis of non-randomized clinical data.

Trial registration

Clinicaltrials.govNCT00206635.

SUBMITTER: Goodin DS 

PROVIDER: S-EPMC3227563 | biostudies-literature | 2011

REPOSITORIES: biostudies-literature

altmetric image

Publications

Establishing long-term efficacy in chronic disease: use of recursive partitioning and propensity score adjustment to estimate outcome in MS.

Goodin Douglas S DS   Jones Jason J   Li David D   Traboulsee Anthony A   Reder Anthony T AT   Beckmann Karola K   Konieczny Andreas A   Knappertz Volker V  

PloS one 20111130 11


<h4>Context</h4>Establishing the long-term benefit of therapy in chronic diseases has been challenging. Long-term studies require non-randomized designs and, thus, are often confounded by biases. For example, although disease-modifying therapy in MS has a convincing benefit on several short-term outcome-measures in randomized trials, its impact on long-term function remains uncertain.<h4>Objective</h4>Data from the 16-year Long-Term Follow-up study of interferon-beta-1b is used to assess the rel  ...[more]

Similar Datasets

| S-EPMC5522120 | biostudies-literature
| S-EPMC3169671 | biostudies-literature
| S-EPMC4941430 | biostudies-literature
| S-EPMC3862210 | biostudies-literature
| S-EPMC7872589 | biostudies-literature
| S-EPMC9380155 | biostudies-literature
| S-EPMC5497217 | biostudies-literature
| S-EPMC5408373 | biostudies-literature
| S-EPMC7092449 | biostudies-literature
| S-EPMC9425894 | biostudies-literature